Related Experiment Video
Updated: Jul 1, 2026
12:41
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
Organoid technology in cancer research.
1Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Molecular Biomedicine
|June 29, 2026
Summary
Organoid technology offers a powerful preclinical cancer model, improving drug discovery and personalized medicine. Patient-derived organoids (PDOs) show promise as biomarkers for predicting treatment response in cancer patients.
Area of Science:
- Oncology
- Developmental Biology
- Biotechnology
Background:
- Organoid technology recapitulates human tumor complexity, overcoming limitations of traditional cancer models.
- Over 15 years, organoids have evolved from a specialized technique to a versatile platform for cancer research.
Purpose of the Study:
- To provide a comprehensive overview of organoid systems in cancer research.
- To highlight applications from basic research to clinical personalized medicine.
- To discuss challenges and future directions for clinical translation.
Main Methods:
- Review of fundamental biological principles and standardized methodologies for tumor organoid establishment.
- Integration of single-cell multi-omics, spatial profiling, and bioengineering.
- Analysis of therapeutic development strategies and clinical trials using patient-derived organoids (PDOs).
Main Results:
- Organoid models provide mechanistic insights into tumor initiation, evolution, and metastasis.
- Organoids advance high-throughput drug discovery, functional precision oncology, and immuno-oncology.
- Patient-derived organoids (PDOs) are validated as predictive biomarkers for treatment response.
Conclusions:
- Organoid technology is a critical tool for understanding cancer biology and developing novel therapeutics.
- Clinical trials demonstrate the potential of PDOs in guiding personalized cancer treatment.
- Addressing current challenges will accelerate the clinical translation of organoids for improved patient outcomes.
